AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29601268 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent aerobic and strength training, three 60-minute sessions per week from the 17th gestational week until delivery
Number of subjects: 47
Study 29601591 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-based case management intervention (SUCCESS)
Number of subjects: 113
Study 29601591 — intervention group
Group type: COMPARATOR
Intervention: Usual services (control)
Number of subjects: 113
Study 29601591 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (intervention and control)
Number of subjects: 113
Study 29601591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 113
Study 29601591 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study 29601618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pliaglis (self-occluding eutectic mixture of lidocaine and tetracaine)
Number of subjects: 581
Study 29602324 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise psychotherapy intervention
Number of subjects: 570
Study 29602324 — intervention group
Group type: COMPARATOR
Intervention: Information session
Number of subjects: 570
Study 29602324 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure attachment
Number of subjects: 570
Study 29602324 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious-preoccupied attachment
Number of subjects: 570
Study 29602324 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearful-avoidant attachment
Number of subjects: 570
Study 29602473 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizon stent graft (Endospan, Herzliya, Israel); 14F profile system, single access site
Number of subjects: 40
Study 29602767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual loading antiplatelet therapy with aspirin and P2Y
Number of subjects: 5887
Study 29602793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking before and after meal intake
Number of subjects: 23
Study 29602793 — intervention group
Group type: COMPARATOR
Intervention: No smoking (control group)
Number of subjects: 23
Study 29602793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma concentrations of glucagon
Number of subjects: 23
Study 29602794 — intervention group
Group type: EXPERIMENTAL
Intervention: NASH patients
Number of subjects: 28
Study 29602842 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyponatraemia
Number of subjects: 405
Study 29602842 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia
Number of subjects: 405
Study 29602842 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired eGFR
Number of subjects: 405
Study 29603015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulixertinib (BVD-523) at a recommended phase 2 dose of 600 mg BID
Number of subjects: 105
Study 29603015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulixertinib (BVD-523)
Number of subjects: 105
Study 29603017 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-wearable light therapy for 60 min daily for 5 weeks
Number of subjects: 8
Study 29603017 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-wearable light therapy
Number of subjects: 8
Study 29603539 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29603764 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose lenalidomide (10 mg) plus dexamethasone (Rdex)
Number of subjects: 41
Study 29604189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 137
Study 29605019 — intervention group
Group type: EXPERIMENTAL
Intervention: QoR-15 score classification
Number of subjects: 276
Study 29605203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat (using test VHC)
Number of subjects: 0
Study 29605203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat
Number of subjects: 0
Study 29605216 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 203
Study 29605216 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma
Number of subjects: 203
Study 29605216 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially controlled asthma
Number of subjects: 203
Study 29605216 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled asthma
Number of subjects: 203
Study 29605216 — intervention group
Group type: EXPERIMENTAL
Intervention: High ICS doses
Number of subjects: 203
Study 29605405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime estrogen (E) exposure
Number of subjects: 385
Study 29605405 — intervention group
Group type: EXPERIMENTAL
Intervention: E-free period
Number of subjects: 385
Study 29605469 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM)
Number of subjects: 71483
Study 29605469 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 71483
Study 29605469 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term type 2 diabetes mellitus (≥20 years)
Number of subjects: 71483
Study 29605494 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma proteins associated with β-carotene
Number of subjects: 500
Study 29605494 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma proteins associated with lutein/zeaxanthin
Number of subjects: 500
Study 29605494 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma proteins associated with β-cryptoxanthin
Number of subjects: 500
Study 29605494 — intervention group
Group type: COMPARATOR
Intervention: Plasma proteins associated with α-carotene
Number of subjects: 500
Study 29605494 — intervention group
Group type: COMPARATOR
Intervention: Plasma proteins associated with lycopene
Number of subjects: 500
Study 29605573 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Nutrition Pathway for Acute Care (INPAC) including Canadian Nutrition Screening Tool and Subjective Global Assessment (SGA)
Number of subjects: 5030
Study 29605813 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents born very preterm with BPD and asthma symptoms
Number of subjects: 0
Study 29605813 — intervention group
Group type: COMPARATOR
Intervention: Controls (not explicitly defined in the abstract)
Number of subjects: 0
Study 29606114 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised multi-station exercise program (7 stations with exercises of increasing difficulty)
Number of subjects: 85
Study 29606114 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised multi-station exercise program
Number of subjects: 85
Study 29606114 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of more than three of five identified prognostic factors
Number of subjects: 85
Study 29606114 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of three or fewer of five identified prognostic factors
Number of subjects: 85
Study 29606148 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (5 hours per week for 4 weeks via videoconference)
Number of subjects: 80
Study 29606148 — intervention group
Group type: COMPARATOR
Intervention: Standard Speech and Language Therapy (usual care)
Number of subjects: 80
Study 29606148 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 80
Study 29606415 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75mg every 2 weeks (Q2W) added to statin therapy (atorvastatin ≥10mg/day or rosuvastatin ≥5mg/day), with a potential increase to 150mg Q2W if LDL-C remains ≥100mg/dL at week 12.
Number of subjects: 0
Study 29606415 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) with atorvastatin ≥10mg/day or rosuvastatin ≥5mg/day, with dose adjustment to achieve LDL-C <100mg/dL.
Number of subjects: 0
Study 29606586 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib, administered orally (capsule or liquid), twice daily on a continuous 28-day schedule, in increasing doses adjusted for age and bodyweight. Doses included 100 mg twice daily (cohort 1) and 150 mg twice daily (cohort 2).
Number of subjects: 24
Study 29606665 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) monotherapy
Number of subjects: 579
Study 29606665 — intervention group
Group type: COMPARATOR
Intervention: Combination ETN plus csDMARD
Number of subjects: 579
Study 29607050 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg UDCA for 12 weeks followed by 50 mg sitagliptin for 12 weeks (UDCA-first group)
Number of subjects: 16
Study 29607050 — intervention group
Group type: COMPARATOR
Intervention: 50 mg sitagliptin for 12 weeks followed by 900 mg UDCA for 12 weeks (sitagliptin-first group)
Number of subjects: 16
Study 29607050 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg UDCA
Number of subjects: 16
Study 29607216 — intervention group
Group type: EXPERIMENTAL
Intervention: AT TORBI 709M IOL (Carl Zeiss Meditec AG)
Number of subjects: 59
Study 29607216 — intervention group
Group type: COMPARATOR
Intervention: Tecnis toric aspheric IOL (Abbot Medical Optics)
Number of subjects: 59
Study 29608412 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic Detailing intervention
Number of subjects: 87
Study 29608508 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine-18-fluorodeoxyglucose (F-FDG) PET parameters including SUVmax, SUVpeak, SUVmean, metabolic tumor volume, entropy
Number of subjects: 44
Study 29608508 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of cytoplasmic HIF-1α (score 3)
Number of subjects: 44
Study 29608508 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean CD8-TILs
Number of subjects: 44
Study 29608508 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed scoring system based on identified prognostic factors
Number of subjects: 44
Study 29608532 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound size greater than 200 cm²
Number of subjects: 112
Study 29608532 — intervention group
Group type: COMPARATOR
Intervention: Overall sample
Number of subjects: 112
Study 29608533 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg twice daily
Number of subjects: 118
Study 29608587 — intervention group
Group type: EXPERIMENTAL
Intervention: Flolan (epoprostenol) solution prepared with the reformulated pH 12.0 diluent
Number of subjects: 10
Study 29608587 — intervention group
Group type: COMPARATOR
Intervention: Flolan (epoprostenol) solution prepared with the existing pH 10.5 diluent
Number of subjects: 10
Study 29608711 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected with gorilla SFV
Number of subjects: 24
Study 29608711 — intervention group
Group type: COMPARATOR
Intervention: Control group (not infected with SFV)
Number of subjects: 24
Study 29608809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy
Number of subjects: 0
Study 29608809 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty
Number of subjects: 0
Study 29608809 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 0
Study 29608901 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture-second strategy
Number of subjects: 16
Study 29608901 — intervention group
Group type: COMPARATOR
Intervention: Posture-first strategy
Number of subjects: 16
Study 29608972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple sparing mastectomy
Number of subjects: 0
Study 29608972 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative methodological approaches (propensity score and CUSUM)
Number of subjects: 0
Study 29609000 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating in the absence of hunger (EAH) at age 4.5 years
Number of subjects: 158
Study 29609000 — intervention group
Group type: EXPERIMENTAL
Intervention: High EAH intakes at age 4.5 years
Number of subjects: 158
Study 29609000 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy consumed during EAH task
Number of subjects: 158
Study 29609000 — intervention group
Group type: EXPERIMENTAL
Intervention: EAH behaviour
Number of subjects: 158
Study 29609000 — intervention group
Group type: EXPERIMENTAL
Intervention: EAH
Number of subjects: 158
Study 29609000 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions aimed at reducing responsiveness to external food cues
Number of subjects: 158
Study 29609013 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (64 mg, 160 mg, 320 mg, 480 mg)
Number of subjects: 250
Study 29609013 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (all doses)
Number of subjects: 250
Study 29609013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 29609013 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 250
Study 29609532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) discontinuation with regular monitoring
Number of subjects: 173
Study 29609536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate sodium alignment (DNa)
Number of subjects: 0
Study 29609536 — intervention group
Group type: COMPARATOR
Intervention: Control group (well-matched control patients)
Number of subjects: 0
Study 29609555 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured multidisciplinary lifestyle program
Number of subjects: 100
Study 29609705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory surgery
Number of subjects: 203
Study 29609706 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled nitric oxide as a biomarker for screening for obstructive sleep apnea in pregnancy
Number of subjects: 76
Study 29609706 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum sleep apnea assessment
Number of subjects: 76
Study 29609706 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined screening models with exhaled nitric oxide and additional parameters
Number of subjects: 76
Study 29609868 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nut supplementation (1 Brazil nut per day for 8 weeks)
Number of subjects: 130
Study 29609868 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nut supplementation
Number of subjects: 130
Study 29609867 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian score (AU) for girls
Number of subjects: 248
Study 29609867 — intervention group
Group type: COMPARATOR
Intervention: Circadian score (AU) for boys
Number of subjects: 248
Study 29609867 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian-Function-Index for children
Number of subjects: 248
Study 29609867 — intervention group
Group type: COMPARATOR
Intervention: Circadian-Function-Index for adults
Number of subjects: 248
Study 29609994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nellix System (Endologix, Inc) for endovascular aneurysm sealing (EVAS)
Number of subjects: 333
Study 29610111 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard education enhanced with the connected system
Number of subjects: 60
Study 29610111 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes education
Number of subjects: 60
Study 29610115 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2), Lenalidomide, Ibrutinib
Number of subjects: 0
Study 29610121 — intervention group
Group type: EXPERIMENTAL
Intervention: ERBB3-Directed Targeted Therapy
Number of subjects: 0
Study 29610659 — intervention group
Group type: COMPARATOR
Intervention: CCLG group (chemotherapy with less local treatment)
Number of subjects: 647
Study 29610659 — intervention group
Group type: EXPERIMENTAL
Intervention: GPOH group (chemotherapy with more local treatment)
Number of subjects: 647
Study 29610659 — intervention group
Group type: COMPARATOR
Intervention: CCLG group (compared to GPOH)
Number of subjects: 647
Study 29610943 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation for IBD patients with iron deficiency (ID)
Number of subjects: 353
Study 29610943 — intervention group
Group type: COMPARATOR
Intervention: Restless legs syndrome (RLS) in patients with inflammatory bowel disease (IBD)
Number of subjects: 353
Study 29610943 — intervention group
Group type: COMPARATOR
Intervention: Restless legs syndrome (RLS)
Number of subjects: 353
Study 29610945 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (BMI > 30)
Number of subjects: 288
Study 29610945 — intervention group
Group type: COMPARATOR
Intervention: Non-obese group (BMI < 29.9)
Number of subjects: 288
Study 29611022 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2141795 (75 mg daily)
Number of subjects: 0
Study 29611427 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior atrial fibrillation (AF)
Number of subjects: 10568
Study 29611427 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset atrial fibrillation (AF)
Number of subjects: 10568
Study 29611427 — intervention group
Group type: COMPARATOR
Intervention: Patients without atrial fibrillation (AF)
Number of subjects: 10568
Study 29613921 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of 6-month anti-lipopolysaccharide IgG
Number of subjects: 107
Study 29613921 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of 6-month anti-flagellin IgA
Number of subjects: 107
Study 29613921 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of 6-month anti-flagellin IgG
Number of subjects: 107
Study 29613921 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of citrulline at 6 months
Number of subjects: 107
Study 29613921 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of RBP at 6 months
Number of subjects: 107
Study 29613921 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma citrulline and vitamin A status
Number of subjects: 107
Study 29613921 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel markers for EED
Number of subjects: 107
Study 29613921 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of systemic inflammation
Number of subjects: 107
Study 29614389 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of Active Psychotic Symptoms (DAT)
Number of subjects: 307
Study 29614389 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cut-off of DAT
Number of subjects: 307
Study 29614389 — intervention group
Group type: EXPERIMENTAL
Intervention: Premorbid adjustment
Number of subjects: 307
Study 29614389 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 307
Study 29614955 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploid genotype calls in WS group
Number of subjects: 38
Study 29614955 — intervention group
Group type: EXPERIMENTAL
Intervention: Triploid genotype calls in Dup7 group
Number of subjects: 38
Study 29614955 — intervention group
Group type: EXPERIMENTAL
Intervention: G allele of SNP rs2528795 in ELN gene
Number of subjects: 38
Study 29614955 — intervention group
Group type: EXPERIMENTAL
Intervention: A allele of SNP rs2528795 in ELN gene
Number of subjects: 38
Study 29614983 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 371
Study 29614983 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers with lung cancer
Number of subjects: 371
Study 29614983 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers with H&N cancer
Number of subjects: 371
Study 29614997 — intervention group
Group type: EXPERIMENTAL
Intervention: Study-specific questionnaires measuring level of knowledge about disease and treatment.
Number of subjects: 98
Study 29614997 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-INFO25 questionnaire assessing perception of and satisfaction with received information.
Number of subjects: 98
Study 29615082 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and dexamethasone (KRd)
Number of subjects: 0
Study 29615082 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 0
Study 29615093 — intervention group
Group type: EXPERIMENTAL
Intervention: automated, continuous control of endotracheal cuff pressure
Number of subjects: 600
Study 29615093 — intervention group
Group type: COMPARATOR
Intervention: intermittent measurement and control of endotracheal cuff pressure using a manual cuff pressure meter
Number of subjects: 600
Study 29615093 — intervention group
Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 600
Study 29615407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasta in the context of low-GI dietary patterns
Number of subjects: 2448
Study 29615445 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT and contingency management (CM+)
Number of subjects: 54
Study 29615445 — intervention group
Group type: COMPARATOR
Intervention: CBT alone (CBT)
Number of subjects: 54
Study 29615448 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest and thumb ECG monitoring using Coala Heart Monitor for 28 days
Number of subjects: 0
Study 29615448 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessment using short-form health survey (SF-36)
Number of subjects: 0
Study 29615448 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility assessment of the Coala Heart Monitor
Number of subjects: 0
Study 29615450 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound scan (CEUS)
Number of subjects: 0
Study 29615450 — intervention group
Group type: COMPARATOR
Intervention: Time-resolved CT angiography (tCTA)
Number of subjects: 0
Study 29615488 — intervention group
Group type: EXPERIMENTAL
Intervention: Genedrive HCV assay
Number of subjects: 422
Study 29615873 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29616144 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation programme, 'The Healthy Brain Rehabilitation Manual'
Number of subjects: 46000
Study 29616236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined water, sanitation, handwashing, and nutrition
Number of subjects: 8246
Study 29616236 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing
Number of subjects: 8246
Study 29616236 — intervention group
Group type: COMPARATOR
Intervention: Active control group (monthly household visits to measure child mid-upper arm circumference)
Number of subjects: 8246
Study 29616236 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 8246
Study 29616235 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined water, sanitation, handwashing, and nutrition
Number of subjects: 5551
Study 29616235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition group
Number of subjects: 5551
Study 29616235 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 5551
Study 29616235 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention or health promoter visit)
Number of subjects: 5551